Download or read book Therapy for Ocular Angiogenesis written by Arup Das and published by Lippincott Williams & Wilkins. This book was released on 2012-03-28 with total page 896 pages. Available in PDF, EPUB and Kindle. Book excerpt: Ocular angiogenesis, or the abnormal growth of blood vessels in the eye, is the cause of major neovascular eye diseases. With the new era of anti-angiogenic therapies, ophthalmologists have started treating many ocular diseases including macular degeneration, diabetic retinopathy, and retinal vascular occlusion using anti-angiogenic drugs. This book covers the basic pathophysiology of ocular angiogenesis and strategies for inhibition. The authors discuss the "Principles" of anti-angiogenic therapy, pre-clinical studies, future drugs on the horizon, drug delivery, and the "Practice" of the therapy in many ocular diseases. The book also includes chapters on diabetic macular edema, and various therapeutic options for this condition. A companion website includes the fully searchable text and an image bank.
Download or read book Ocular Angiogenesis written by Joyce Tombran-Tink and published by Springer Science & Business Media. This book was released on 2007-11-06 with total page 412 pages. Available in PDF, EPUB and Kindle. Book excerpt: Leading academic and pharmaceutical researchers and clinicians from many disciplines synthesize and summarize current clinical and basic knowledge concerning abnormal growth of blood vessels in the eye, the cause of major neovascular eye diseases. The authors also identify and assess the most promising approaches with potential for commercial exploitation and discuss the challenges encountered in developing therapeutics for ocular neovascular diseases. Highlights include illuminating chapters on gene therapy and novel drug delivery systems and excellent summaries of the newest therapeutic approaches.
Download or read book Retinal and Choroidal Angiogenesis written by John Penn and published by Springer Science & Business Media. This book was released on 2008-01-19 with total page 567 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides a comprehensive, in-depth review of our current understanding of the growth of blood vessels within the eye. Novel therapeutic strategies for the treatment of ocular angiogenesis are discussed, as are the unique challenges presented by delivery of drugs to the eye. The book emphasizes basic principles rather than specific experimental results, although recently acquired data is frequently cited to illustrate points of broader theoretical significance.
Download or read book Anti Angiogenic Therapy in Ophthalmology written by Andreas Stahl and published by Springer. This book was released on 2016-05-13 with total page 193 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides a concise overview over the pathology of retinal angiogenic diseases and explains why anti-angiogenic therapy is effective in so many patients. The reader is guided through the various clinical indications for anti-angiogenic therapy and made aware of its merits as well as current challenges and limitations. It is explained how, since its introduction for the treatment of exudative age-related macular degeneration in 2006, anti-angiogenic therapy has revolutionized the way in which we treat a range of ocular diseases. All of the authors are established experts in their respective fields who share their extensive knowledge and clinical experience with the reader. This book is both a valuable introduction to anti-angiogenic therapy in ophthalmology and a day-to-day companion for all ophthalmologists seeing patients with some of the most prevalent retinal diseases.
Download or read book Anti VEGF written by M. Battaglia Parodi and published by Karger Medical and Scientific Publishers. This book was released on 2010-08-13 with total page 155 pages. Available in PDF, EPUB and Kindle. Book excerpt: The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability. The advantages over conventional laser photocoagulation are evident as laser treatment always leaves scars and causes a retinal sensitivity deterioration.Starting with an outline of treatment principles, this volume covers all aspects of anti-VEGF therapy for ophthalmological disorders. In particular, specific chapters are dedicated to age-related macular degeneration, degenerative myopia, angioid streaks, inflammatory diseases, hereditary dystrophies, retinal vein occlusion, diabetic retinopathy, ocular tumors, as well as anterior segment neovascularization.The book gives an update on the application of anti-VEGF in ocular diseases to general ophthalmologists as well as retina specialists.
Download or read book Inhibitors of corneal inflammation and angiogenesis written by Pierfrancesco Mirabelli and published by Linköping University Electronic Press. This book was released on 2019-04-30 with total page 91 pages. Available in PDF, EPUB and Kindle. Book excerpt: Pathologic angiogenesis is involved in cancer and several blinding conditions such as wet age-related macular degeneration, proliferative retinopathies and corneal neovascularization. In these dieseases, the angiogenic triggers are hypoxia and inflammation, and both involve the main angiogenic mediator, which is Vascular Endothelial Growth Factor (VEGF). Among available treatments, anti-VEGF often shows limited or temporary efficacy, while steroids are potentially responsible for many side-effects. This thesis presents a series of linked studies aimed at elucidating the early pathologic changes leading to inflammation and corneal neovascularization, and how various treatments affect this process. In this thesis, anti-inflammatory and anti-angiogenic treatments are applied in corneal neovascularization models, to identify VEGF-independent pathways and other novel factors as future therapy targets, as well as to investigate the endogenous modulation of angiogenesis. A model of experimental neovascularization in the rat cornea was used as main model, where the neovascular response is triggered by a surgical suture placed into the cornea. Investigational treatments (anti-Vegf, dexamethasone, IMD0354, Gap27, or control substances) were then given topically, with the exception of IMD0354, which was given systemically. The effects in the cornea were studied in vivo with slit lamp photography to assess and quantify macroscopic vessel growth and using in vivo confocal microscopy (IVCM) to study cell infiltration and limbal vessel dilation and detect microscopic vessel sprouts; these examinations were performed longitudinally. Genomic analysis with RNA microarray, selected gene expression with q-RT-PCR, and selected protein expression in tissue (immunohistochemistry, immunofluorescence, Western blot) were performed at different time-points. Moreover, other experiments on cell cultures (HUVEC and HCEC), organ cultures (human corneas), ex vivo models (aortic rings) and in vivo studies (zebrafish vasculogenesis) were performed. Dexamethasone suppressed limbal vasodilation and corneal neovascularization more than anti-Vegf, despite no difference in inflammatory cell infiltration into the cornea. Five-hundred eleven fewer genes were differentially expressed in dexamethasone-treated corneas relative to naïve corneas, compared to anti-Vegf. Among them, several major pro-angiogenic and pro-inflammatory factors and chemokines were suppressed only by dexamethasone and represent novel candidate factors to target in order to improve anti-VEGF treatment. On the other hand, selective inhibition of a single inflammatory pathway (NF-?B), despite showing similar early effects as dexamethasone in suppressing tissue inflammation, was not effective enough to suppress new vessel growth. The same factors suppressed by dexamethasone are also inhibited in endogenous modulation of angiogenesis. Surprisingly, dexamethasone activated several complement factors, which could possibly be beneficial in the anti-angiogenic response. In a different therapeutic approach, promoting cell migration to accelerate epithelial wound closure similarly was not sufficient to avoid inflammation and angiogenesis in the cornea. In conclusion, new and more effective treatments are needed for corneal inflammation and neovascularization with fewer side-effects. In this thesis, several novel factors and mechanisms related to inflammation are identified, factors that are not addressed by anti-Vegf therapy, and therefore represent interesting objects for further study, as they have the potential to be targets for adjuvant therapy. Specific anti-inflammatory treatment as well as therapeutic activation of endogenous regulatory pathways, and potentially complement modulation, might represent new strategies to improve anti-angiogenic therapy, but when used alone they do not seem to avoid corneal neovascularization.
Download or read book Regulation of inflammation and angiogenesis in the cornea written by Anthony Mukwaya and published by Linköping University Electronic Press. This book was released on 2018-05-21 with total page 55 pages. Available in PDF, EPUB and Kindle. Book excerpt: Inflammation and angiogenesis, the growth of new blood vessels from pre-existing ones, are involved in tumor growth, ocular diseases and wound healing. In ocular angiogenesis, new pathological vessels grow into a specific eye tissue, leak fluid, and disrupt vision. The development of safe and effective therapies for ocular angiogenesis is of great importance for preventing blindness, given that current treatments have limited efficacy or are associated with undesirable side effects. The search for alternative treatment targets requires a deeper understanding of inflammation and how it can lead to angiogenesis in the eye in pathologic situations. This thesis provides new insights into the regulation of inflammation and angiogenesis, particularly at the gene expression and phenotypic levels, in different situations characterized by angiogenesis of the cornea, often called corneal neovascularization. For instance, specific genes and pathways are either endogenously activated or suppressed during active inflammation, wound healing, and during resolution of inflammation and angiogenesis, serving as potential targets to modulate the inflammatory and angiogenic response. In addition, as part of the healing response to restore corneal transparency, inflammation and angiogenesis subside with time in the cornea. In this context, LXR/RXR signaling was found to be activated in a time-dependent manner, to potentially regulate resolution of inflammation and angiogenesis. During regression of new angiogenic capillaries, ghost vessels and empty basement membrane sleeves are formed, which can persist in the cornea for a long time. Here, ghost vessels were found to facilitate subsequent revascularization of the cornea, while empty basement membrane sleeves did not revascularize. The revascularization response observed here was characterised by vasodilation, increased inflammatory cell infiltration and by sprouting at the front of the reperfused vessels. Importantly, reactive oxygen species and nitrous oxide signaling among other pro-inflammatory pathways were activated, and at the same time anti-inflammatory LXR/RXR signaling was inhibited. The interplay between activation and inhibition of these pathways highlights potential mechanisms that regulate corneal revascularization. When treating corneal neovascularization clinically, corticosteroids are in widespread use due to their effectiveness. To minimize the many undesirable side effects associated with corticosteroid use, however, identifying new and more selective agents is of great importance. Here, it was observed that corticosteroids not only suppressed pro-inflammatory chemokines and cytokines, but also activated the classical complement pathway. Classical complement may represent a candidate for further selective therapeutic manipulation to investigate its effect on treatment of corneal neovascularization. In summary, this thesis identifies genes, pathways, and phenotypic responses involved in sprouting and remodeling of corneal capillaries, highlights novel pathways and factors that may regulate inflammation and angiogenesis in the cornea, and provides insights into regulation of capillary regression and reactivation. Further investigation of these regulatory mechanisms may offer alternative and effective treatment targets for the treatment of corneal inflammation and angiogenesis.
Download or read book Pharmacologic Therapy of Ocular Disease written by Scott M. Whitcup and published by Springer. This book was released on 2017-06-05 with total page 394 pages. Available in PDF, EPUB and Kindle. Book excerpt: There have been major advancements in the pharmacologic treatment of eye diseases over the past decade. With newly discovered disease targets and novel approaches to deliver therapeutic compounds to the eye, patients are seeing improved outcomes. Not only are there better treatments for diseases where treatments existed, we now have effective therapy for previously untreatable and blinding eye disorders. This volume will cover the pharmacologic treatment of eye diseases from the front of the eye including eyelids, conjunctiva and cornea all the way back to the retina and optic nerve. The first section of the volume reviews general principles of ocular pharmacology, pharmacokinetics, pharmaceutical sciences, and drug delivery. In addition, the volume provides an up to date guide to the pharmacologic approach to the key eye diseases that threaten sight or ocular function.
Download or read book Therapeutic Antibodies written by Yuti Chernajovsky and published by Springer. This book was released on 2007-11-22 with total page 380 pages. Available in PDF, EPUB and Kindle. Book excerpt: This essential work, edited by two researchers at London’s famous Queen Mary’s medical school targets one of the most important areas in medical development today. These days, antibody therapeutics are the treatment of choice for several autoimmune and oncological conditions. They are, indeed, becoming the molecules of choice for further combination therapies and cell engineering. In this timely work, a slew of expert in the field of drug development summarize all the current developments and clinical successes.
Download or read book Endogenous Inhibitors of Angiogenesis TSP1 and PEDF as Potential Targets for Treatment of Exudative AMD written by Mitra Farnoodian and published by . This book was released on 2016 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: Abstract Age-related macular degeneration (AMD) is a major causes of visual impairment in the elderly population worldwide. The increased production of vascular endothelial growth factor (VEGF) has been identified as an essential factor in development and progression of AMD, and choroidal neovascularization (CNV). Intravitreal injection of VEGF antagonists is effective in delaying CNV and pathological progression of the disease. However, safety concerns are emerging regarding long term blockade of VEGF, and loss of ocular integrity due to multiple intravitreal injections and systemic complications. Thus, safe and effective new treatments are needed. Pigment epithelium derived factor (PEDF) and thrombospondin-1 (TSP1) are major endogenous inhibitors of ocular angiogenesis which are deficient in vascular retinopathies including human AMD. Small peptides derived from their active fragments are potently anti-angiogenic in models of ocular diseases and tumors. Our preliminary results indicated that these peptides attenuate CNV in pre-clinical models of exudative AMD. Although the pathogenesis of AMD has been associated with retinal pigmented epithelium (RPE) impairment and choroidal vascular dysfunction, the detailed mechanisms remain unresolved. Choroidal endothelial cells (ChEC) have a crucial role in maintaining the health of outer retina and photoreceptor function. RPE cells also play a key role in the development and stabilization of retinal structure, and maintenance of the ocular vascular hemostasis. They assist in the maintenance of the ocular angiogenic balance by production of positive and negative regulatory factors including VEGF, TSP1, and PEDF. The altered production of PEDF and TSP1, as endogenous inhibitors of angiogenesis and inflammation, has been linked to pathogenesis of AMD and CNV. The molecular pathways affected by ChEC and RPE cells impairment leading to clinically relevant AMD changes need further investigation. These studies are hampered by the lack of availability of methods to readily culture ChEC and RPE cells from wild type and transgenic mice retina. In the present study, using our unique method for routine culturing of ChEC and RPE cells from wild type and transgenic mice, I examined, for the first time, the cell autonomous impact of PEDF and TSP1 on ChEC and RPE cell function. I proposed a novel approach to investigate the potential effect of TSP1 and PEDF expression on ChEC and RPE cell function and their contribution in AMD pathologies. In addition, I used small peptides mimicking the action of these endogenous inhibitors, TPS1 and PEDF, to investigate if they utilize similar mechanisms of action as the whole molecules on ChEC and RPE function. Replacing this inhibitory function should provide beneficial effects for ocular neovascular disease including AMD where the natural inhibitors level is low or absent. The results of these studies showed that the expression of PEDF and/ or TSP1 by ChEC and RPE cells has a crucial role not only in modulation of ocular vascular homeostasis but also have significant influence on their cellular function and their alteration may contribute to pathogenesis of AMD. Furthermore, PEDF and TSP1 mimetic peptides could be potential therapeutics for treatment of AMD.
Download or read book Physiologic and Pathologic Angiogenesis written by Dan Simionescu and published by BoD – Books on Demand. This book was released on 2017-04-05 with total page 466 pages. Available in PDF, EPUB and Kindle. Book excerpt: The purpose of this book is to highlight novel advances in the field and to incentivize scientists from a variety of fields to pursue angiogenesis as a research avenue. Blood vessel formation and maturation to capillaries, arteries, or veins is a fascinating area which can appeal to multiple scientists, students, and professors alike. Angiogenesis is relevant to medicine, engineering, pharmacology, and pathology and to the many patients suffering from blood vessel diseases and cancer, among others. We are hoping that this book will become a source of inspiration and novel ideas for all.
Download or read book Retinal Pharmacotherapeutics written by Q.D. Nguyen and published by Karger Medical and Scientific Publishers. This book was released on 2015-10-27 with total page 408 pages. Available in PDF, EPUB and Kindle. Book excerpt: The use of pharmacotherapeutics in the management of retinal diseases is rapidly evolving, and a favorable therapy for the patient. Today anti-VEGF agents are used for a range of indications from inflammation-related choroidal neovascularization to macular edema secondary to retinal vein occlusion or diabetic retinopathy. Beyond VEGF, there is an array of target areas under investigation – not only for vascular pathologies such as age-related macular degeneration and diabetic eye disease, but also for degenerative, infectious and inflammatory retinal conditions. This publication discusses many aspects from basic research on the retina, to animal models for retinal drug delivery, retinal diseases that are amenable to pharmacotherapy and also drugs and mechanisms in retinal diseases. Anyone concerned with the management of retinal diseases - the general ophthalmologist and the retina specialist alike – will find this book indispensable reading.
Download or read book Angiogenesis Assays written by Carolyn A. Staton and published by John Wiley & Sons. This book was released on 2007-01-11 with total page 410 pages. Available in PDF, EPUB and Kindle. Book excerpt: Angiogenesis, the development of new blood vessels from the existing vasculature, is essential for physiological growth and over 18,000 research articles have been published describing the role of angiogenesis in over 70 different diseases, including cancer, diabetic retinopathy, rheumatoid arthritis and psoriasis. One of the most important technical challenges in such studies has been finding suitable methods for assessing the effects of regulators of eh angiogenic response. While increasing numbers of angiogenesis assays are being described both in vitro and in vivo, it is often still necessary to use a combination of assays to identify the cellular and molecular events in angiogenesis and the full range of effects of a given test protein. Although the endothelial cell - its migration, proliferation, differentiation and structural rearrangement - is central to the angiogenic process, it is not the only cell type involved. the supporting cells, the extracellular matrix and the circulating blood with its cellular and humoral components also contribute. In this book, experts in the use of a diverse range of assays outline key components of these and give a critical appraisal of their strengths and weaknesses. Examples include assays for the proliferation, migration and differentiation of endothelial cells in vitro, vessel outgrowth from organ cultures, assessment of endothelial and mural cell interactions, and such in vivo assays as the chick chorioallantoic membrane, zebrafish, corneal, chamber and tumour angiogenesis models. These are followed by a critical analysis of the biological end-points currently being used in clinical trials to assess the clinical efficacy of anti-angiogenic drugs, which leads into a discussion of the direction future studies should take. This valuable book is of interest to research scientists currently working on angiogenesis in both the academic community and in the biotechnology and pharmaceutical industries. Relevant disciplines include cell and molecular biology, oncology, cardiovascular research, biotechnology, pharmacology, pathology and physiology.
Download or read book Angiogenesis written by Napoleone Ferrara and published by CRC Press. This book was released on 2006-08-15 with total page 304 pages. Available in PDF, EPUB and Kindle. Book excerpt: Why a new book on angiogenesis and why now? For the first time concepts proposed over 30 years ago have found clinical validation. In the last two years the first antiangiogenic agents have been approved by the FDA for the treatment of cancer and age-related macular degeneration. Not surprisingly, this clinical success has raised a new set of basic
Download or read book Therapeutic Angiogenesis for Vascular Diseases written by Mark Slevin and published by Springer Science & Business Media. This book was released on 2010-10-11 with total page 438 pages. Available in PDF, EPUB and Kindle. Book excerpt: Angiogenesis is the growth of new blood vessels and is a key process which occurs during pathological disease progression. Excessive and damaging angiogenesis occurs in diseases such as cancer, diabetic retinopathies, age-related macular degeneration and atherosclerosis. In other diseases such as stroke and myocardial infarction, insufficient or improper angiogenesis results in tissue loss and ultimately higher morbidity and mortality. In this book we will begin by providing the reader with an overview of the process of angiogenesis including normal embryological development of blood vessels. The following chapters will each focus on a key angiogenic disease incorporating current scientific knowledge concerning the causes of activation of the “angiogenic switch”, pathological consequences, current treatment options and future perspectives. Where appropriate, results from pre-clinical trials, novel imaging modalities and nanotechnological approaches will be incorporated into these sections. Finally, since it is now believed that the process of angiogenesis operated via different signalling mechanisms in different vascular beds, we will discuss our current understanding of this phenomenon. The target audience for this book would include researchers in all the basic sciences; post-graduate students at Universities and Institutes; pharmaceutical industries; clinicians working in vascular biology or tissue imaging; pathologists; neurologists; tumour biologists; ophthalmologists and cardiologists.
Download or read book Tumor Angiogenesis written by Dieter Marmé and published by Springer. This book was released on 2019-10-18 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: This exhaustive work shows that new therapies using anti-angiogenic drugs are of particular importance because they can be used against many different types of cancer, as tumor angiogenesis seems to be involved in most if not all solid metastasizing malignancies. The first part of this book summarizes the knowledge acquired on the molecular entities that play a role in tumor angiogenesis and their mechanisms of action. Furthermore, the identification of molecular markers and their validation as predictive and/or prognostic tools is reviewed. In the second and most important part, the clinical applications of anti-angiogenic treatments are documented for a wide variety of tumors. In particular, the modes of combination with other targeted and/or cytotoxic cancer therapies are presented.
Download or read book Human Embryonic Stem Cells written by Jon Odorico and published by Garland Science. This book was released on 2004-02-01 with total page 391 pages. Available in PDF, EPUB and Kindle. Book excerpt: Since the first successful isolation and cultivation of human embryonic stem cells at the University of Wisconsin, Madison in 1998, there has been high levels of both interest and controversy in this area of research. This book provides a concise overview of an exciting field, covering the characteristics of both human embryonic stem cells and pluripotent stem cells from other human cell lineages. The following chapters describe state-of-the-art differentiation and characterization of specific ectoderm, mesoderm and endoderm-derived lineages from human embryonic stem cells, emphasizing how these can be used to study human developmental mechanisms. A further chapter discusses genetic manipulation of human ES cells. The concluding section covers therapeutic applications of human ES cells, as well as addressing the ethical and legal issues that this research have raised.
